other material
confidence high
sentiment positive
materiality 0.60
Niagen Bioscience raises FY2025 net sales growth guidance to 25%-30% YoY
Niagen Bioscience, Inc.
- Full-year 2025 net sales outlook raised to 25%-30% YoY growth from prior 22%-27%.
- CEO cites FDA reversal on DSHEA drug preclusion rule for NMN as potential awareness driver.
- Press release notes every NMN supplement tested infringes on Niagen's patent portfolio.
- Niagen (patented NR) claims superior bioavailability vs. NMN, with three in four NMN products failing label claims.